Observational Study of BRAF Inhibitor Combination Therapy for BRAF mutant Metastatic Colorectal Cancer including Biomarker Research: BEETS trial(JACCRO CC-18) - BEETS trial(JACCRO CC-18)

Start Date01 Oct 2021

Sponsor / Collaborator

DNA Chip Research, Inc.

NCT04904328

/ Unknown statusNot Applicable

A Proof of Concept Clinical Investigation Designed to Evaluate the Performance of Lumishade® Lens With Frame in Alleviating the Symptoms of Photosensitive Migraine.

This proof of concept clinical study will investigate the efficacy of active lens with frame in alleviating the symptoms of migraine which are caused by photosensitivity.
The spectacles cut out blue light wavelength and hypothetically alleviate symptoms of migraine and thus either treat or prevent migraine headaches from occurring.

Start Date30 Jun 2021

Sponsor / Collaborator

Mitsui Chemicals, Inc.

100 Clinical Results associated with Mitsui Chemicals, Inc.

0 Patents (Medical) associated with Mitsui Chemicals, Inc.

1,356

Literatures (Medical) associated with Mitsui Chemicals, Inc.

01 Mar 2025·Journal of Atherosclerosis and Thrombosis

Development and Validation of a Cardiovascular Disease Risk Prediction Model for the Japanese Working Population: The Japan Epidemiology Collaboration on Occupational Health Study

Article

Author: Hu, Huan ; Mizoue, Tetsuya ; Kochi, Takeshi ; Ogasawara, Takayuki ; Yamamoto, Shuichiro ; Nakagawa, Tohru ; Dohi, Seitaro ; Konishi, Maki ; Miyamoto, Toshiaki ; Okazaki, Hiroko ; Kabe, Isamu ; Honda, Toru ; Gommori, Naoki ; Yamamoto, Makoto ; Inoue, Yosuke

AIMSThis study aimed to develop a cardiovascular disease (CVD) risk model using data from a large occupational cohort.METHODSA risk prediction model was developed using the routine health checkup data of 96,117 Japanese employees (84.0% men) who were 30-64 years of age and had no CVD at baseline. Cox proportional hazards regression models were employed to develop a risk model for assessing the 10-year CVD risk. Measures of discrimination and calibration were used to assess the predictive performance of the model and internal validation was used to examine potential overfitting.RESULTSDuring a mean follow-up period of 6.7 years (range, 0.1-11.0 years), 422 cases of incident CVD were confirmed. The final model, which included predictor variables of age, smoking, diabetes, systolic blood pressure, and low- and high-density lipoprotein cholesterol levels, demonstrated a good predictive ability (Harrell's C-statistic, 0.796; 95% confidence interval, 0.775-0.817) with excellent calibration between observed and predicted values. Internal validation revealed minimal overfitting.CONCLUSIONSThe developed model can accurately predict the 10-year CVD risk. Because it is based on routine health checkup data, the prediction model can be easily implemented in the workplace. Further studies are required to assess the external validity and transferability of the proposed CVD risk model.

01 Mar 2025·Journal of Epidemiology and Community Health

Impact of the COVID-19 pandemic on the incidence of cardiometabolic risk factors among workers: results from the Japan Epidemiology Collaboration on Occupational Health study

Article

Author: Kabe, Isamu ; Yamamoto, Shuichiro ; Gonmori, Naoki ; Nakagawa, Tohru ; Ogasawara, Takayuki ; Dohi, Seitaro ; Honda, Toru ; Yamamoto, Makoto ; Yamamoto, Kenya ; Inoue, Yosuke ; Miyamoto, Toshiaki ; Yamamoto, Shohei ; Konishi, Maki ; Kochi, Takeshi ; Ide, Hiroshi ; Mizoue, Tetsuya ; Yokoya, Toshitaka ; Okazaki, Hiroko ; Islam, Zobida

BackgroundThe COVID-19 pandemic and associated restrictions on human activities have greatly changed lifestyles, which might have deteriorated the cardiometabolic profile.ObjectiveThis study aimed to examine the effect of the COVID-19 pandemic on the incidence of cardiometabolic risk factors among Japanese workers in fiscal years (FY) 2020 and 2021 compared with the prepandemic period.MethodThis study comprised an average of 71 025 employees in Japan who underwent annual health check-ups for at least two successive years from 2015 to 2021. Annual incidence rates from 2016 to 2021 were assessed for obesity, diabetes, hypertension, dyslipidaemia and metabolic syndrome (MetS). The observed incidence rates in 2020 and 2021 were compared with the predicted incidence based on prepandemic trends (2016 to 2019).ResultsRelative to the prepandemic, the incidence of all the outcomes, except for dyslipidaemia, significantly increased in 2020. Between FY 2016 and 2019, the adjusted mean incidence of obesity, diabetes, hypertension, dyslipidaemia and MetS was 5.0%, 1.4%, 5.3%, 17.4% and 7.6%, respectively. In FY 2020, the adjusted incidence (95% CI) of these outcomes increased to 6.02 (5.80 to 6.24), 1.84 (1.73 to 1.96), 6.62 (6.40 to 6.83), 19.31 (18.83 to 19.78) and 8.51 (8.23 to 8.78), which were higher than the predicted incidence of 5.24 (4.99 to 5.49), 1.54 (1.41 to 1.67), 6.02 (5.76 to 6.27), 18.58 (18.00 to 19.16) and 8.05 (7.71 to 8.38) for 2020, respectively. The incidence returned to the prepandemic levels in FY 2021.ConclusionResults showed a worsening of the cardiometabolic profile during the initial year of the pandemic, which was reverted in the second year to the levels before the pandemic.

01 Mar 2025·Chemical Engineering and Processing - Process Intensification

Model analysis of mass transfer in liquid films in a Taylor flow reactor for gas-liquid-solid three-phase reactions

Author: Yasuda, Masahiro ; Fukui, Takuya ; Horie, Takafumi

This study focused on the mass transfer characteristics in a Taylor flow reactor using α-methylstyrene hydrogenation as a model reaction.Specifically, the impact of liquid film thickness on the mass transfer rate was investigated.An aluminum tube with palladium-supported alumina on the inner wall was employed as a structured catalyst.The liquid film thickness between the gas slug and the inner wall was adjusted by manipulating the gas-liquid flow rates to study its impact on the reaction rate.It was found that the reaction rate inversely correlates with the liquid film thickness and directly correlates with the gas holdup.A significant discrepancy was observed when comparing the exptl. reaction rates with those predicted by existing models.Anal. of the gas-solid mass transfer revealed that the increased diffusion distance, due to the catalyst surface roughness, was crucial.The reaction rate could be accurately predicted within ±20 % of the exptl. values by incorporating surface roughness into the diffusion distance.Correctly determining the liquid film thickness is essential to accurately predict the hydrogenation rate under conditions dominated by mass transfer through the liquid film.

News (Medical) associated with Mitsui Chemicals, Inc.

03 Feb 2025

·in.marketscreener.com

Mitsui Chemicals, Inc. proposed to acquire remaining 86.13% stake in DNA Chip Research Inc. for ¥6.4 billion.

Mitsui Chemicals, Inc. (TSE:4183) proposed to acquire remaining 86.13% stake in DNA Chip Research Inc. (TSE:2397) for ¥6.4 billion on February 4, 2025. A cash consideration valued at ¥1100 per share will be paid by Mitsui Chemicals for 5,823,062 shares. The Board of Directors of DNA Chip Research Inc. formed a special committee for the transaction. The expected completion of the transaction is April 7, 2025. Mizuho Securities Co., Ltd. acted as tender offer agent and Rakuten Securities, Inc. acted as deputy agent to Mitsui Chemicals. KPMG FAS Co., Ltd. acted as financial advisor for Mitsui Chemicals, Inc. Mori Hamada & Matsumoto LPC acted as legal advisor for Mitsui Chemicals, Inc. Plutus Consulting Co., Ltd. acted as financial advisor for DNA Chip Research Inc. Nishimura & Asahi acted as legal advisor for DNA Chip Research Inc.

Acquisition

02 Feb 2025

·www.marketscreener.com

Mitsui Chemicals, Inc. proposed to acquire remaining 86.13% stake in DNA Chip Research Inc. for ¥6.4 billion.

Acquisition

24 Oct 2024

·www.mobihealthnews.com

Dyania Health secures $10M in Series A round led by HealthX Ventures

Dyania Health, an AI-enabled healthcare data company, announced the close of a $10 million Series A funding round led by HealthX, TechSquare and Cleveland Clinic Ventures with participation from existing investors. WHAT IT DOES The company's Synapsis AI platform automates the reading and analysis of medical data, intending to allow more streamlined and ideal clinical research, report and quality within healthcare institutions. The company said its platform will be implemented in large healthcare systems to uncover enterprise-wide clinical trial pre-screening, run automated chart reviews for observational studies and automate elaborate registry reporting. "The healthcare industry continues to struggle with inefficiencies in managing unstructured data and delays in clinical trial recruitment," Eirini Schlosser, CEO and cofounder of Dyania Health, told MobiHealthNews in an email. "This funding enables us to accelerate our mission of transforming healthcare data management through AI. By expanding our AI capabilities, we can address critical inefficiencies in clinical research and patient care. The new investment will allow us to further develop our Synapsis AI platform, which is already revolutionizing the speed and accuracy of medical data analysis. With this support, we will continue scaling our technology to meet the growing demand from healthcare systems and life sciences companies." MARKET SNAPSHOT In 2022, Dyania Health announced a $5.3 million seed round led by Innospark Ventures. Wild Basin, Outsiders Fund, Tau Ventures, Genesis Ventures and TLife Investments participated in the round. Other players in the healthcare data space include Verana Health, which in 2022 secured $150 million in Series E funding, which the company used to expand its life sciences products across the drug development process as well as improve its data network for providers. It also added new data partnerships, including ones with medical societies. The round was led by Johnson & Johnson Innovation with participation from Novo Growth. GV (Google Ventures), Casdin Capital, Brook Byers, Merck Global Health Innovation Fund, THVC and Breyer Capital. In 2019, TriNetX raised $40 million in a Series D funding round led by Merck Global Health Innovation Fund. Mitsui & Co. and Itochu Technology Ventures and returning financial backers MPM Capital, F2 Ventures and Deerfield Management participated in the round.

100 Deals associated with Mitsui Chemicals, Inc.

100 Translational Medicine associated with Mitsui Chemicals, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 29 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

MS-180(Mitsui Chemicals, Inc.) ( GP IIb/IIIa )	Thromboembolism More	Discontinued
MS-31050 ( Sodium-hydrogen exchangers )	Myocardial Ischemia More	Pending
MS-31038 ( Sodium-hydrogen exchangers )	Myocardial Ischemia More	Pending
IMGM ( Sodium-hydrogen exchangers )	Myocardial Ischemia More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Mitsui Chemicals, Inc.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 29 May 2025

Current Projects

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing